NewsBenzingaXBiotech宣布其多中心TASKIN临床研究II期部分数据达到Simon两阶段设计下预先设定的主要疗效成功标准；Vilamakitug试验组61.3%的参与者存活，超过42%的阈值，更多患者存活 XBiotech宣布其多中心TASKIN临床研究II期部分数据达到Simon两阶段设计下预先设定的主要疗效成功标准；Vilamakitug试验组61.3%的参与者存活，超过42%的阈值，更多患者存活 Benzinga 2026.10.19 13:03 (GMT+0) Open on Benzinga Other news Anthropic Could Take Major IPO Step as Soon as Friday: What Investors Need to Know Senator Rand Paul Warns ‘Free’ Government Benefits Come With Higher Taxes — Says US Cannot Afford ‘Trillions More’ as Debt Tops $40 Trillion Micron Introduces Quarterly Profit-Linked Bonuses Worldwide Following Taiwan Union Demands For Profit-Sharing Meta Strikes 8-Year Deal to Keep Mark Zuckerberg in California as Billionaire Tax Looms: ‘Critically Important’ for Him to Remain in Leadership 'TSMC Seeks Factory-Equipment Alternatives To Thwart China's Rare Earths Grip, Sources Say' - Reuters Exclusive Nokia Sees Q4 Sales $7.118B-$7.355B vs $7.300B Est
Senator Rand Paul Warns ‘Free’ Government Benefits Come With Higher Taxes — Says US Cannot Afford ‘Trillions More’ as Debt Tops $40 Trillion
Micron Introduces Quarterly Profit-Linked Bonuses Worldwide Following Taiwan Union Demands For Profit-Sharing
Meta Strikes 8-Year Deal to Keep Mark Zuckerberg in California as Billionaire Tax Looms: ‘Critically Important’ for Him to Remain in Leadership
'TSMC Seeks Factory-Equipment Alternatives To Thwart China's Rare Earths Grip, Sources Say' - Reuters Exclusive
